News

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bank of America is breaking with the Fed's wait-and-see approach and pushing for rate hikes now, which reshuffles the entire investing playbook. Four dividend-paying stocks across the sectors that quietly thrive when borrowing costs climb deserve a closer look.

Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.

Alexandria Real Estate Equities (NYSE:ARE) has delivered a 427,000 RSF research and development facility for Bristol Myers Squibb at its San Diego megacampus. The new state-of-the-art R&D hub marks an operational milestone for the company and reflects demand from a large multinational pharmaceutical tenant. Alexandria Real Estate Equities focuses on life science and R&D campuses that serve large pharmaceutical and biotech companies. The new San Diego facility for Bristol Myers Squibb adds...

Bristol Myers Squibb (NYSE:BMY) is rolling out new AI infrastructure built on NVIDIA's latest architecture to support drug discovery. The company is applying this technology across oncology, cardiovascular disease and other core therapeutic areas. Bristol Myers Squibb has opened a 427,000 square foot R&D hub at the Campus Point Megacampus in San Diego. The new site is intended to bring together research teams and laboratory capacity in a single large West Coast center. Bristol Myers Squibb...

This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.

Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.

BMS enhances its AI computing power as big pharma race to stay competitive within the shifting global landscape.

Drugmaker deploys NVIDIA DGX SuperPOD with Vera Rubin systems to accelerate medicine discovery.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

The drugmaker will deploy NVIDIA's Vera Rubin systems, giving it what it calls the most powerful AI computing infrastructure in life sciences

The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were up, as chipma

Bristol Myers Squibb (NYSE:BMY) has expanded its artificial intelligence collaboration with Nvidia (NASDAQ:NVDA), announcing plans to deploy an Nvidia DGX SuperPOD powered by DGX Vera Rubin NVL72 systems to strengthen its AI infrastructure for drug discovery and development. The expansion builds on a partnership that began nearly three years ago and is designed to provide significantly greater computing power for AI-driven research.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia ‌to support its use of artificial intelligence across its drug discovery and development ‌operations. The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD ​based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to its last close.

The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.

FDA has accepted Bristol Myers Squibb's New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The filing is supported by a Phase 3 trial that showed a meaningful improvement in progression free survival for this patient group. This decision marks a key regulatory milestone for NYSE:BMY's oncology pipeline and could influence how investors view its future revenue mix. Bristol-Myers Squibb enters this news cycle...

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

Drug pricing matters, but pipelines matter even more.

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.